CG
VNDA icon

Cutler Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Cutler Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,250
Closed -$98K – 6117
2021
Q4 		$98K Buy
+6,250
New +$109K ﹤0.01% 1870
2018
Q3 		– Sell
-100
Closed -$1K – 4759
2018
Q2 		$1K Hold
100
– – ﹤0.01% 3975
2018
Q1 		$1K Buy
+100
New +$1.67K ﹤0.01% 4186
2017
Q4 		– Sell
-1,400
Closed -$20.8K – 6026
2017
Q3 		$25K Buy
+1,400
New +$23.4K ﹤0.01% 2930
2017
Q1 		– Sell
-2,586
Closed -$41K – 7288
2016
Q4 		$41K Sell
2,586
-13,930
-84% -$224K ﹤0.01% 2753
2016
Q3 		$274K Buy
16,516
+15,879
+2,493% +$214K 0.01% 977
2016
Q2 		$7K Buy
+637
New +$6.17K ﹤0.01% 4629
2016
Q1 		– Sell
-55
Closed -$451 – 7273
2015
Q4 		$0 Buy
+55
New +$549 ﹤0.01% 6383

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Cutler Group's VNDA Position: Q1 2022 in Review

Cutler Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 6,250 shares — an estimated $98K sold.

Cutler Group first reported a position in VNDA in Q4 2015 and held it in 8 quarters. The position peaked at $274K in Q3 2016. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

  • Cutler Group reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 6,250 Vanda Pharmaceuticals shares in Q1 2022, an estimated $98K.
  • Cutler Group first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Vanda Pharmaceuticals position peaked at $274K in Q3 2016.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.